Studies of the Neutralizing Activity and Avidity of Anti-Human Immunodeficiency Virus Type 1 Env Antibody Elicited by DNA Priming and Protein Boosting

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Journal of Virology

• Publication date

  1998-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/JVI.72.11.9092-9100.1998PMID 9765454PMCID PMC110326
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions.

  1998cited by this paper
• Immunogenicity of Recombinant Vaccinia Viruses that Display the HIV Type 1 Envelope Glycoprotein on the Surface of Infectious Virions

  1997cited by this paper
• Anti-HIV env immunities elicited by nucleic acid vaccines.

  1997cited by this paper
• Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process

  1997cited by this paper
• Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination.

  1997cited by this paper
• Challenge of chimpanzees immunized with a recombinant canarypox-HIV-1 virus.

  1997cited by this paper
• Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting.

  1997influential reference
• Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex

  1997cited by this paper
• Early studies on DNA-based immunizations for measles virus.

  1997cited by this paper
• Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination

  1997cited by this paper
• Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1

  1997cited by this paper
• Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit.

  1997cited by this paper
• Vaccine-specific antibody responses induced by HIV-1 envelope subunit vaccines.

  1997cited by this paper
• Enhancement of immunodeficiency virus-specific immune responses in DNA-immunized rhesus macaques.

  1997cited by this paper
• Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160

  1997cited by this paper
• Human retroviruses and AIDS 1997

  1997cited by this paper
• DNA vaccines for immunodeficiency viruses.

  1997cited by this paper
• Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity

  1997influential reference
• DNA vaccines for immunodeficiency viruses.

  1997cited by this paper
• An Investigation of the High-Avidity Antibody Response to Glycoprotein 120 of Human Immunodeficiency Virus Type 1

  1997cited by this paper
• Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals

  1997cited by this paper
• HIV-1 Env glycoproteins from two series of primary isolates: replication phenotype and immunogenicity.

  1997influential reference
• Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein

  1996cited by this paper
• Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors.

  1996cited by this paper
• Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

  1996cited by this paper
• Induction of immunodeficiency virus‐specific immune responses in rhesus monkeys following gene gun‐mediated DNA vaccination

  1996cited by this paper
• Role of different lymphoid tissues in the initiation and maintenance of DNA-raised antibody responses to the influenza virus H1 glycoprotein

  1996cited by this paper
• Human immunodeficiency virus type 1 envelope protein endocytosis mediated by a highly conserved intrinsic internalization signal in the cytoplasmic domain of gp41 is suppressed in the presence of the Pr55gag precursor protein

  1996cited by this paper
• Safety and Immunogenicity of a Recombinant HIV Type 1 Glycoprotein 160 Boosted by a V3 Synthetic Peptide in HIV-Negative Volunteers

  1995cited by this paper
• HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells.

  1995cited by this paper
• Human studies in the development of human immunodeficiency virus vaccines.

  1995cited by this paper
• Candidate AIDS vaccines.

  1995cited by this paper
• Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer

  1995cited by this paper
• Endocytosis of endogenously synthesized HIV-1 envelope protein. Mechanism and role in processing for association with class II MHC.

  1995cited by this paper
• Simian Immunodeficiency Virus DNA Vaccine Trial in Macaques

  1995cited by this paper
• Differential Role of V3-Specific Antibodies in Neutralization Assays Involving Primary and Laboratory-Adapted Isolates of HIV Type 1

  1995cited by this paper
• Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines.

  1995cited by this paper
• DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans.

  1995cited by this paper
• Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus

  1995influential reference
• Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice.

  1995cited by this paper
• Measuring Vaccine-Induced HIV Neutralization: Report of a Workshop

  1994cited by this paper
• A Qualitative Progression in HIV Type 1 Glycoprotein 120-Specific Cytotoxic Cellular and Humoral Immune Responses in Mice Receiving a DNA-Based Glycoprotein 120 Vaccine

  1994cited by this paper
• Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies.

  1994cited by this paper
• Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities

  1994cited by this paper
• Measurement of antibody avidity for hepatitis C virus distinguishes primary antibody responses from passively acquired antibody

  1994cited by this paper
• Germinal centers.

  1994cited by this paper
• Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network.

  1994cited by this paper
• Augmentation of Human Immunodeficiency Virus Type 1 Neutralizing Antibody by Priming with gp160 Recombinant Vaccinia and Boosting with gp160 in Vaccinia-Naive Adults

  1993cited by this paper
• Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.

  1993cited by this paper
• Gene inoculation generates immune responses against human immunodeficiency virus type 1.

  1993cited by this paper
• Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.

  1993cited by this paper
• Secretion of a truncated form of the human immunodeficiency virus type 1 envelope glycoprotein.

  1993cited by this paper
• V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.

  1993cited by this paper
• Artifacts with the thiocyanate elution method for estimating relative antibody avidity.

  1993cited by this paper
• DNA Inoculation Induces Neutralizing Immune Responses Against Human Immunodeficiency Virus Type 1 in Mice and Nonhuman Primates

  1993cited by this paper
• Germinal Centers and Antibody Production in Bone Marrow

  1992cited by this paper
• Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160.

  1992cited by this paper
• Cross-Neutralizing Antibodies in Rabbits Immunized with HIV-1 gp160 Purified from Simian Cells Infected with a Recombinant Vaccinia Virus

  1991cited by this paper
• Antibody avidity following varicella‐zoster virus infections

  1991cited by this paper
• Neutralizing Antibodies Against HIV-1 BRU and SF2 Isolates Generated in Mice Immunized with Recombinant Vaccinia Virus Expressing HIV-1 (BRU) Envelope Glycoproteins and Boosted with Homologous gp160

  1991cited by this paper
• Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses

  1991cited by this paper
• A novel enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies to HIV-1 envelope glycoproteins based on immobilization of viral glycoproteins in microtiter wells coated with concanavalin A.

  1990cited by this paper
• Affinity distributions of antigen-specific IgG in patients with multiple sclerosis and in patients with viral encephalitis.

  1990cited by this paper
• Active and passive immunization against Plasmodium yoelii sporozoites.

  1990cited by this paper
• Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells.

  1990cited by this paper
• Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay

  1988cited by this paper
• Human retroviruses and AIDS.

  1988cited by this paper
• Enzyme-linked immunosorbent assay determination of specific rubella antibody levels in micrograms of immunoglobulin G per milliliter of serum in clinical samples

  1978cited by this paper

• Glycan-reactive antibodies isolated from human HIV-1 vaccine trial participants show broad pathogen cross-reactivity

  2025cites this paper
• Glycan-reactive antibodies isolated from human HIV-1 vaccine trial participants show broad pathogen cross-reactivity

  2025cites this paper
• Robust and protective immune responses induced by heterologous prime‐boost vaccination with DNA‐protein dimeric RBD vaccines for COVID‐19

  2023cites this paper
• Mix-and-Match COVID-19 Vaccinations (Heterologous Boost): A Review

  2022cites this paper
• Immunogenicity of MultiTEP-Platform-Based Recombinant Protein Vaccine, PV-1950R, Targeting Three B-Cell Antigenic Determinants of Pathological α-Synuclein

  2022cites this paper
• Immunogenicity of MultiTEP platform technology-based Tau vaccine in non-human primates

  2022cites this paper
• In vitro and in vivo inhibition of malaria parasite infection by monoclonal antibodies against Plasmodium falciparum circumsporozoite protein (CSP)

  2021cites this paper
• Enhancement of piscine orthoreovirus-2 DNA vaccine potency by linkage of antigen gene to a trigger factor gene or signal peptide genes

  2020cites this paper
• A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

  2020cites this paper
• Comparison of Codon Optimized and Non-Optimized Influenza HA DNA Vaccines

  2019cites this paper
• One Group's Historical Reflections on DNA Vaccine Development

  2018cites this paper
• The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients

  2017cites this paper
• How to assess the binding strength of antibodies elicited by vaccination against HIV and other viruses

  2016cites this paper
• Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants

  2016cites this paper
• Strong, but Age-Dependent, Protection Elicited by a Deoxyribonucleic Acid/Modified Vaccinia Ankara Simian Immunodeficiency Virus Vaccine

  2016cites this paper
• A comparative approach between heterologous prime-boost vaccination strategy and DNA vaccinations for rabies.

  2015cites this paper
• What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure?

  2015cites this paper
• Enhanced Immunogenicity of an HIV-1 DNA Vaccine Delivered with Electroporation via Combined Intramuscular and Intradermal Routes

  2014cites this paper
• Enhanced immunogenicity of a HIV-1 DNA vaccine delivered with electroporation via

  2014cites this paper
• DNA Immunization for HIV Vaccine Development

  2014cites this paper
• Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines

  2014cites this paper
• Design and development of cationic liposomes as DNA vaccine adjuvants

  2013cites this paper
• Vaccination studies with the mper of HIV-1 gp41 grafted into transmembrane protein of a gammaretrovirus

  2013cites this paper
• Adjuvant-Specific Serum Cytokine Profiles in the Context of a DNA Prime-Protein Boost HIV-1 Vaccine: A Dissertation

  2013cites this paper
• Synthetic DNA vaccine strategies against persistent viral infections

  2013cites this paper
• Mucosal Application of gp140 Encoding DNA Polyplexes to Different Tissues Results in Altered Immunological Outcomes in Mice

  2013cites this paper
• Progress on the Induction of Neutralizing Antibodies Against HIV Type 1 (HIV-1)

  2012cites this paper
• DNA Vaccines

  2012influential citation
• A Pilot Study Comparing the Development of EIAV Env-Specific Antibodies Induced by DNA/Recombinant Vaccinia-Vectored Vaccines and an Attenuated Chinese EIAV Vaccine

  2012cites this paper
• SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses.

  2012cites this paper
• Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially.

  2012cites this paper
• Broader Neutralizing Antibodies against H5N1 Viruses Using Prime-Boost Immunization of Hyperglycosylated Hemagglutinin DNA and Virus-Like Particles

  2012cites this paper
• HIV vaccine design based on in vivo evolution of quasispecies envelope proteins

  2012cites this paper
• Immunization with Multiple Vaccine Modalities Induce Strong HIV-Specific Cellular and Humoral Immune Responses

  2012cites this paper
• Comparison of immune response generated against Japanese encephalitis virus envelope protein expressed by DNA vaccines under macrophage associated versus ubiquitous expression promoters

  2011cites this paper
• The strategic use of novel smallpox vaccines in the post-eradication world

  2011cites this paper
• DNA vaccines: an historical perspective and view to the future

  2011cites this paper
• Intradermal naked plasmid DNA immunization: mechanisms of action

  2011cites this paper
• Strategies to enhance the potency of HIV-1 DNA vaccines

  2011cites this paper
• DNA Vaccines for Infectious Diesase

  2011cites this paper
• Antibody Responses Elicited by DNA Prime-Protein Boost HIV Vaccines: A Dissertation

  2010cites this paper
• DNA prime–protein boost increased the titer, avidity and persistence of anti-Aβ antibodies in wild-type mice

  2010cites this paper
• Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity.

  2010cites this paper
• Fusion of C3d molecule with neutralization epitope(s) of hepatitis E virus enhances antibody avidity maturation and neutralizing activity following DNA immunization.

  2010cites this paper
• Enhancement of humoral and cellular immunity in mice against Japanese encephalitis virus using a DNA prime-protein boost vaccine strategy.

  2010cites this paper
• [Enzymatic immunoassays for the detection of infectious agents or their products: presentation of some designs and applications].

  2010cites this paper
• Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope.

  2009cites this paper
• DNA Vaccines for Biodefense and Emerging and Neglected Infectious Diseases

  2009cites this paper
• Heterologous prime-boost vaccination.

  2009cites this paper
• DNA vaccines against influenza viruses.

  2009influential citation
• Working towards an HIV/AIDS vaccine

  2009cites this paper
• Contribución a la utilización de los anticuerpos como herramientas analíticas y diagnósticas

  2009cites this paper
• Structure, Immunopathogenesis and Vaccines Against SARS Coronavirus

  2008cites this paper
• Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope.

  2008influential citation
• Prevention of the sexual transmission of HIV-1: preparing for success

  2008cites this paper
• Effect of a Codon Optimized DNA Prime on Induction of Anti-Influenza Protective Antibodies

  2007cites this paper
• Prime-boost immunization strategies against HIV-1

  2007cites this paper
• The degree of apoptosis as an immunostimulant for a DNA vaccine against HIV-1 infection.

  2007cites this paper
• Proteomic analysis of augmented immune responses in mouse by prime-and-boost immunization strategy with DNA vaccine coding HBsAg and rHBsAg protein.

  2007cites this paper
• Characterization of the antibody response elicited by HIV-1 Env glycomutants in rabbits.

  2007cites this paper
• Evaluation of T-cell responses to peptides with MHC class I-binding motifs derived from PE_PGRS 33 protein of Mycobacterium tuberculosis.

  2007cites this paper
• Effect of a Codon Optimized DNA Prime on Induction of Anti-Influenza Protective Antibodies

  2007cites this paper
• A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120.

  2007cites this paper
• Intracellular accumulation of a 46 kDa species of mouse prion protein as a result of loss of glycosylation in cultured mammalian cells.

  2006cites this paper
• Immune Enhancement Mechanisms by the Complement Protein C3d

  2006cites this paper
• Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.

  2006cites this paper
• Combination DNA plus protein HIV vaccines

  2006influential citation
• Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine.

  2006cites this paper
• Characterization of Immune Responses Elicited in Macaques Immunized Sequentially with Chimeric VEE/SIN Alphavirus Replicon Particles Expressing SIVGag and/or HIVEnv and with Recombinant HIVgp140Env Protein

  2006cites this paper
• C3d enhances immune responses using low doses of DNA expressing the HIV-1 envelope from codon-optimized gene sequences.

  2005cites this paper
• Enhanced Immunogenicity of gp120 Protein When Combined with Recombinant DNA Priming To Generate Antibodies That Neutralize the JR-FL Primary Isolate of Human Immunodeficiency Virus Type 1

  2005influential citation
• Molecular mechanisms of HIV-1 associated neurodegeneration

  2005cites this paper
• Focus on Increasing Potency and Efficacy

  2005cites this paper
• Polyvalent DNA prime and envelope protein boost HIV‐1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate

  2005cites this paper
• Mouse strain-dependent differences in enhancement of immune responses by C3d.

  2004cites this paper
• Multiprotein HIV Type 1 Clade B DNA/MVA Vaccine: Construction, Safety, and Immunogenicity in Macaques

  2004cites this paper
• Sub-fragments of the envelope gene are highly protective against the Japanese encephalitis virus lethal infection in DNA priming--protein boosting immunization strategies.

  2004cites this paper
• Human Immunodeficiency Virus Type 1 Neutralize the JR-FL Primary Isolate of Priming To Generate Antibodies That When Combined with Recombinant DNA Enhanced Immunogenicity of gp 120 Protein

  2004influential citation
• Elicitation of Neutralizing Antibodies with DNA Vaccines Expressing Soluble Stabilized Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trimers Conjugated to C3d

  2004influential citation
• Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design

  2004cites this paper
• DNA/MVA Vaccine for HIV Type 1: Effects of Codon-Optimization and the Expression of Aggregates or Virus-Like Particles on the Immunogenicity of the DNA Prime

  2004cites this paper
• Delivery of DNA to skin by particle bombardment.

  2004cites this paper
• Gene Delivery to Mammalian Cells

  2003cites this paper
• IL-12/GM-CSF Coadministration in an SIV DNA Prime/Protein Boost Protocol Enhances Gag-Specific T Cells But Not Virus-Specific Neutralizing Antibodies in Rhesus Macaques

  2003cites this paper
• Delivery of polynucleotides and oligonucleotides for improving immune responses to vaccines

  2003cites this paper
• Needle-free topical electroporation improves gene expression from plasmids administered in porcine skin.

  2003cites this paper
• Expression and Immunogenicity of Sequence-Modified Human Immunodeficiency Virus Type 1 Subtype B pol and gagpol DNA Vaccines

  2003cites this paper
• Immunogenicity in Mamu-A*01 rhesus macaques of a CCR5-tropic human immunodeficiency virus type 1 envelope from the primary isolate (Bx08) after synthetic DNA prime and recombinant adenovirus 5 boost.

  2003cites this paper
• Gene Vaccines

  2003cites this paper
• A DNA‐priming protein‐boosting regimen significantly improves type 1 immune response but not protective immunity to Trypanosoma cruzi infection in a highly susceptible mouse strain

  2003cites this paper
• Enhancement of Antibodies to the Human Immunodeficiency Virus Type 1 Envelope by Using the Molecular Adjuvant C3d

  2003cites this paper
• Protective effects of vaccination with bovine leukemia virus (BLV) Tax DNA against BLV infection in sheep.

  2003cites this paper
• Purification and Characterization of Oligomeric Envelope Glycoprotein from a Primary R5 Subtype B Human Immunodeficiency Virus

  2002cites this paper
• DNA vaccines against cytomegalovirus: current progress.

  2002cites this paper
• Electroporation improves the efficacy of DNA vaccines in large animals.

  2002cites this paper
• New Approaches For Detecting Recent HIV-1 Infection

  2002cites this paper
• Protection by SIV VLP DNA prime/protein boost following mucosal SIV challenge is markedly enhanced by IL‐12/GM‐CSF co‐administration

  2002cites this paper
• Protection against feline immunodeficiency virus using replication defective proviral DNA vaccines with feline interleukin-12 and -18.

  2002cites this paper
• DNA prime/protein boost vaccine strategy in neonatal macaques against simian human immunodeficiency virus

  2002cites this paper
• Immunization with Influenza Virus Hemagglutinin Globular Region Containing the Receptor-Binding Pocket

  2002cites this paper